SynthesisFrontiers in physiology2026
Comparing potassium-competitive acid blocker-based therapies for
Synthesis in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eradication rates for Aim: To evaluate the efficacy, safety and compliance of PCAB-based regimens for Methods: Randomised controlled trials in adults with Results: Seventy-seven RCTs involving 19,950 patients were included. Vonoprazan (VPZ)-based regimens showed the highest eradication rates in proportional meta-analysis (88.15-91.94%), while tegoprazan (TPZ)- and keverprazan (KEV)-based regimens demonstrated more variable performance. NMA demonstrated a significantly higher eradication rate in patients treated with VPZ-based quadruple regimen compared with VPZ-based dual (OR = 1.47, 95% CI 1.05-2.07) and TPZ-based triple (OR = 3.54, 95% CI 1.21-10.65) regimen. SUCRA ranking identified VPZ-based quadruple as the highest-ranked regimen (93.78%), followed by VPZ-based triple (70.55%) and TPZ-based quadruple (66.22%) regimen, indicating relative treatment ranking probabilities. Compliance rates were comparable across regimens with no significant differences, while VPZ- and TPZ-based dual therapies showed better safety profiles with lower adverse events than quadruple therapies (OR = 0.39-0.42). Conclusions: VPZ-based quadruple therapy demonstrated the highest eradication efficacy among PCAB-based regimens, with significantly superior performance compared with selected dual and triple therapies. VPZ-based dual therapy appears to have a better balance of efficacy and safety profile. However, as 76 of 77 included trials were conducted in Asian populations, these findings should be interpreted with caution when extrapolating to non-Asian settings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/home ID= CRD420251125759 identifier CRD420251125759.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.